A
Alternative Bio
Developing novel therapeutics for intractable cancers
About Alternative Bio
Alternative Bio Inc. is a privately held biotechnology company developing precision medicines to treat difficult cancers by targeting post-translational modifying enzymes. Based in Singapore, the company was established by a team of world-renowned scientists: Dr. Fei Lan, Dr. Yang Shi, and Dr. Or Gozani, who bring extensive expertise in cancer biology, signaling, and gene expression regulation. Their collective research has been foundational to several other biotech ventures, including Constellation Pharmaceuticals and K36 Therapeutics.
The company's core mission is to translate groundbreaking discoveries related to protein synthesis regulatory nodes into first-in-class therapies. In December 2022, Alternative Bio announced it had secured USD 15 million in a Series Seed financing round. The round was co-led by Eight Roads Ventures and F-Prime Capital, with participation from Sequoia China Seed Fund (now known as Hongshan Capital Group). This capital is being used to advance the company's discovery platform and move its lead drug candidates toward clinical application for treating some of the most intractable cancers.
Alternative Bio operates in the biotechnology and HealthTech sectors, focusing on creating a new class of drugs. The business model is centered on intensive research and development to discover and patent novel therapeutics, with the long-term goal of bringing these precision medicines to cancer patients worldwide.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Headquarters
- Singapore, Singapore
- Open positions
- None listed
- Dealroom signal
- 21.1/100
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Dec 2022 | $15M | $60M | HSG · Eight Roads Ventures · F-Prime | ↗ |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alternative Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alternative Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.